[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX9207382A - Nuevos compuestos que tienen actividad terapeutica intermediarios para su preparacion, proceso para obtencion de tales compuestos y formulacion farmaceutica que los contiene. - Google Patents

Nuevos compuestos que tienen actividad terapeutica intermediarios para su preparacion, proceso para obtencion de tales compuestos y formulacion farmaceutica que los contiene.

Info

Publication number
MX9207382A
MX9207382A MX9207382A MX9207382A MX9207382A MX 9207382 A MX9207382 A MX 9207382A MX 9207382 A MX9207382 A MX 9207382A MX 9207382 A MX9207382 A MX 9207382A MX 9207382 A MX9207382 A MX 9207382A
Authority
MX
Mexico
Prior art keywords
compounds
preparation
intermediary
therapeutic activity
obtaining
Prior art date
Application number
MX9207382A
Other languages
English (en)
Inventor
Bernard Robin Boar
Alan John Cross
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Publication of MX9207382A publication Critical patent/MX9207382A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a compuestos que tienen la fórmula general I que tienen actividad terapéutica, a los intermediarios para su preparación, a las formulaciones farmacéuticas que contienen los compuestos y al uso medicinal de los compuestos y compuestos similares conocidos.
MX9207382A 1991-12-18 1992-12-17 Nuevos compuestos que tienen actividad terapeutica intermediarios para su preparacion, proceso para obtencion de tales compuestos y formulacion farmaceutica que los contiene. MX9207382A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9103752A SE9103752D0 (sv) 1991-12-18 1991-12-18 New compounds

Publications (1)

Publication Number Publication Date
MX9207382A true MX9207382A (es) 1993-07-01

Family

ID=20384648

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9207382A MX9207382A (es) 1991-12-18 1992-12-17 Nuevos compuestos que tienen actividad terapeutica intermediarios para su preparacion, proceso para obtencion de tales compuestos y formulacion farmaceutica que los contiene.

Country Status (23)

Country Link
US (1) US5585378A (es)
EP (1) EP0624156A1 (es)
JP (1) JPH07502272A (es)
CN (1) CN1034939C (es)
AP (1) AP389A (es)
AU (1) AU675055B2 (es)
BG (1) BG98815A (es)
CA (1) CA2124826A1 (es)
CZ (1) CZ146694A3 (es)
EE (1) EE9400428A (es)
FI (1) FI942913A (es)
HU (1) HUT69704A (es)
IL (1) IL104107A0 (es)
IS (1) IS3958A (es)
MX (1) MX9207382A (es)
NO (1) NO942316L (es)
PL (1) PL170736B1 (es)
SE (1) SE9103752D0 (es)
SI (1) SI9200405A (es)
SK (1) SK278321B6 (es)
TN (1) TNSN92114A1 (es)
WO (1) WO1993012085A1 (es)
ZA (1) ZA929700B (es)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620973A (en) * 1993-11-30 1997-04-15 Takeda Chemical Industries, Ltd. Tetracyclic condensed heterocyclic compounds and their use
SE9504267D0 (sv) * 1995-11-29 1995-11-29 Astra Ab New therapeutic use
GB2308362A (en) * 1995-12-19 1997-06-25 Lilly Industries Ltd Pharmaceutical indole derivatives
WO1998007431A1 (en) * 1996-08-22 1998-02-26 New York University Cholinesterase inhibitors for treatment of parkinson's disease
WO1998008816A1 (fr) * 1996-08-26 1998-03-05 Meiji Seika Kaisha, Ltd. Derives d'indoxyle et psychotropes
KR20010041625A (ko) * 1998-03-06 2001-05-25 아스트라제네카 악티에볼라그 신규 용도
GB9810886D0 (en) * 1998-05-13 1998-07-22 Lilly Industries Ltd Pharmaceutical compounds
GB9820489D0 (en) * 1998-09-22 1998-11-11 Steiger Malcolm J Compounds for improved treatment of parkinson's disease
HUP0104493A3 (en) 1998-09-30 2002-12-28 Takeda Pharmaceutical Drugs for improving vesical excretory strength
US6417214B1 (en) 1999-05-04 2002-07-09 Wyeth 3,3-substituted indoline derivatives
US6462032B1 (en) 1999-05-04 2002-10-08 Wyeth Cyclic regimens utilizing indoline derivatives
US6355648B1 (en) 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6358948B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
US6399593B1 (en) 1999-05-04 2002-06-04 Wyeth Cyclic regimens using cyclic urea and cyclic amide derivatives
US6407101B1 (en) 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6423699B1 (en) 1999-05-04 2002-07-23 American Home Products Corporation Combination therapies using benzimidazolones
US6380235B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Benzimidazolones and analogues
US6358947B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Tetracyclic progesterone receptor modulator compounds and methods
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6498154B1 (en) 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
US6369056B1 (en) 1999-05-04 2002-04-09 American Home Products Corporation Cyclic urea and cyclic amide derivatives
US6339098B1 (en) 1999-05-04 2002-01-15 American Home Products Corporation 2,1-benzisothiazoline 2,2-dioxides
US6329416B1 (en) 1999-05-04 2001-12-11 American Home Products Corporation Combination regimens using 3,3-substituted indoline derivatives
US6306851B1 (en) 1999-05-04 2001-10-23 American Home Products Corporation Cyclocarbamate and cyclic amide derivatives
US6444668B1 (en) 1999-05-04 2002-09-03 Wyeth Combination regimens using progesterone receptor modulators
US6380178B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Cyclic regimens using cyclocarbamate and cyclic amide derivatives
US6319912B1 (en) 1999-05-04 2001-11-20 American Home Products Corporation Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides
US6509334B1 (en) 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US20030153598A1 (en) * 2000-07-25 2003-08-14 Raymond Pratt Methods for treating Parkinson's disease with cholinesterase inhibitors
EP2138177A1 (en) * 2000-03-03 2009-12-30 Eisai R&D Management Co., Ltd. Use of a cholinesterase inhibitor for the treatment of dementia and cognitive impairments
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
CN1317276C (zh) * 2000-09-29 2007-05-23 中国科学院上海药物研究所 一类吲哚基哌啶类化合物及其制备方法和用途
JP2004529110A (ja) 2001-03-06 2004-09-24 アストラゼネカ アクチボラグ 脈管損傷活性を有するインドール誘導体
US6770638B2 (en) 2001-04-20 2004-08-03 Spectrum Pharmaceuticals, Inc. Tetrahydroindolone and purine derivatives linked to arylpiperazines
EP1764134B1 (en) * 2001-07-30 2009-01-28 Spectrum Pharmaceuticals, Inc. Purine derivatives linked to arylpiperazines
WO2003011396A1 (en) * 2001-07-30 2003-02-13 Neotherapeutics, Inc. Tetrahydroindolone and purine derivatives linked to arylpiperazines
WO2005030148A2 (en) * 2003-09-25 2005-04-07 Cenomed, Inc. Tetrahydroindolone derivatives for treatment of neurological conditions
US20050107439A1 (en) * 2003-11-10 2005-05-19 Helton David R. Composition and method for treating emesis
GT200500185A (es) * 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
MY150958A (en) * 2005-06-16 2014-03-31 Astrazeneca Ab Compounds for the treatment of multi-drug resistant bacterial infections
US8906360B2 (en) 2005-07-22 2014-12-09 The Board Of Trustees Of The Leland Stanford Junior University Light-activated cation channel and uses thereof
US9238150B2 (en) 2005-07-22 2016-01-19 The Board Of Trustees Of The Leland Stanford Junior University Optical tissue interface method and apparatus for stimulating cells
US8926959B2 (en) 2005-07-22 2015-01-06 The Board Of Trustees Of The Leland Stanford Junior University System for optical stimulation of target cells
US9274099B2 (en) 2005-07-22 2016-03-01 The Board Of Trustees Of The Leland Stanford Junior University Screening test drugs to identify their effects on cell membrane voltage-gated ion channel
US10052497B2 (en) 2005-07-22 2018-08-21 The Board Of Trustees Of The Leland Stanford Junior University System for optical stimulation of target cells
US20090093403A1 (en) 2007-03-01 2009-04-09 Feng Zhang Systems, methods and compositions for optical stimulation of target cells
US8398692B2 (en) 2007-01-10 2013-03-19 The Board Of Trustees Of The Leland Stanford Junior University System for optical stimulation of target cells
WO2008101128A1 (en) 2007-02-14 2008-08-21 The Board Of Trustees Of The Leland Stanford Junior University System, method and applications involving identification of biological circuits such as neurological characteristics
US10035027B2 (en) 2007-10-31 2018-07-31 The Board Of Trustees Of The Leland Stanford Junior University Device and method for ultrasonic neuromodulation via stereotactic frame based technique
US10434327B2 (en) 2007-10-31 2019-10-08 The Board Of Trustees Of The Leland Stanford Junior University Implantable optical stimulators
EP2219648A4 (en) * 2007-11-09 2010-11-03 Cenomed Biosciences Llc TREATMENT OF POSTRAUMATIC STRESS WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS
US20090264443A1 (en) * 2008-04-18 2009-10-22 David Helton Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds
ES2608498T3 (es) 2008-04-23 2017-04-11 The Board Of Trustees Of The Leland Stanford Junior University Sistemas, métodos y composiciones para la estimulación óptica de células diana
JP5890176B2 (ja) 2008-05-29 2016-03-22 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー セカンドメッセンジャーを光制御するためのセルライン、システム、および方法
MX2010014101A (es) 2008-06-17 2011-03-04 Univ Leland Stanford Junior Aparato y metodos para controlar el desarrollo celular.
WO2010006049A1 (en) 2008-07-08 2010-01-14 The Board Of Trustees Of The Leland Stanford Junior University Materials and approaches for optical stimulation of the peripheral nervous system
NZ602416A (en) 2008-11-14 2014-08-29 Univ Leland Stanford Junior Optically-based stimulation of target cells and modifications thereto
WO2010090680A1 (en) * 2008-12-15 2010-08-12 Wyeth Llc Substituted oxindole cb2 agonists
CA2791094A1 (en) 2010-03-17 2011-09-22 The Board Of Trustees Of The Leland Stanford Junior University Light-sensitive ion-passing molecules
US8598156B2 (en) 2010-03-25 2013-12-03 Glaxosmithkline Llc Chemical compounds
CN101863823B (zh) * 2010-06-03 2012-02-08 山东大学 吲哚二酮类化合物及其扩环衍生物、制备方法及应用
EP2635111B1 (en) 2010-11-05 2018-05-23 The Board of Trustees of the Leland Stanford Junior University Stabilized step function opsin proteins and methods of using the same
US8932562B2 (en) 2010-11-05 2015-01-13 The Board Of Trustees Of The Leland Stanford Junior University Optically controlled CNS dysfunction
US9992981B2 (en) * 2010-11-05 2018-06-12 The Board Of Trustees Of The Leland Stanford Junior University Optogenetic control of reward-related behaviors
CN106947741A (zh) 2010-11-05 2017-07-14 斯坦福大学托管董事会 光活化嵌合视蛋白及其使用方法
ES2661093T3 (es) 2010-11-05 2018-03-27 The Board Of Trustees Of The University Of The Leland Stanford Junior University Control y caracterización de la función de la memoria
CN110215614A (zh) 2010-11-05 2019-09-10 斯坦福大学托管董事会 用于光遗传学方法的光的上转换
US8696722B2 (en) 2010-11-22 2014-04-15 The Board Of Trustees Of The Leland Stanford Junior University Optogenetic magnetic resonance imaging
JP6406581B2 (ja) 2011-12-16 2018-10-17 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー オプシンポリペプチドおよびその使用法
ES2728077T3 (es) 2012-02-21 2019-10-22 Univ Leland Stanford Junior Composiciones para el tratamiento de trastornos neurogénicos del suelo pélvico
CN103006642B (zh) * 2013-01-04 2014-10-22 中国药科大学 一类炔亚甲基吲哚-2-酮类衍生物的用途
US9636380B2 (en) 2013-03-15 2017-05-02 The Board Of Trustees Of The Leland Stanford Junior University Optogenetic control of inputs to the ventral tegmental area
JP6594854B2 (ja) 2013-03-15 2019-10-23 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 行動状態の光遺伝学的制御方法
CN105431046B (zh) 2013-04-29 2020-04-17 小利兰·斯坦福大学托管委员会 用于靶细胞中的动作电位的光遗传学调节的装置、系统和方法
CN103242332B (zh) * 2013-05-13 2015-11-04 江西科技师范大学 1-n酰基取代吲哚酮衍生物
CN104530065A (zh) * 2013-05-13 2015-04-22 江西科技师范大学 1-n酰基取代吲哚酮衍生物的应用
CA2921221A1 (en) 2013-08-14 2015-02-19 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for controlling pain
CN103420941B (zh) * 2013-08-26 2015-09-23 浙江大学 2-甲氧基苯基-二甲胺基甲酸酯衍生物及制备和用途
US10568516B2 (en) 2015-06-22 2020-02-25 The Board Of Trustees Of The Leland Stanford Junior University Methods and devices for imaging and/or optogenetic control of light-responsive neurons
US11294165B2 (en) 2017-03-30 2022-04-05 The Board Of Trustees Of The Leland Stanford Junior University Modular, electro-optical device for increasing the imaging field of view using time-sequential capture
CN117624015B (zh) * 2023-12-06 2024-08-16 广东医科大学 一种取代靛红-褪黑激素衍生物及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3573310A (en) * 1967-09-28 1971-03-30 Miles Lab 1-substituted derivatives of 2-indolinone
US3635976A (en) * 1967-12-20 1972-01-18 Pennwalt Corp 1 - heterocyclic alkyl-1 2 3 4-tetrahydroquinazolinones and analgesic intermediates thereof
DE2123923A1 (de) * 1971-05-14 1972-11-23 Boehringer Mannheim Gmbh, 6800 Mannheim 4-eckige Klammer auf omega- (Flavon-7yl-oxy) -alkyl eckige Klammer zu -pigerazin-Derivate und Verfahren zu ihrer Herstellung
GR65270B (en) * 1978-10-10 1980-07-31 Fujisawa Pharmaceutical Co Isatin derivatives and processes for the preparation thereof
US4692448A (en) * 1984-11-20 1987-09-08 Boehringer Ingelheim Pharmaceuticals, Inc. Bis(arylpiperazinyl)sulfur compounds
JPS62294654A (ja) * 1986-06-13 1987-12-22 Kissei Pharmaceut Co Ltd イサチン誘導体
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
FR2651230B1 (fr) * 1989-08-25 1992-03-13 Synthese Rech Derives de la 5-amino-1,2,3,4 tetrahydro-acridine et applications comme medicaments.
RU2124511C1 (ru) * 1993-05-14 1999-01-10 Фармасьютикал Ко., Лтд Производные пиперазина
SE9302080D0 (sv) * 1993-06-16 1993-06-16 Ab Astra New compounds

Also Published As

Publication number Publication date
EE9400428A (et) 1996-04-15
JPH07502272A (ja) 1995-03-09
IS3958A (is) 1993-06-19
TNSN92114A1 (fr) 1993-06-08
NO942316D0 (no) 1994-06-17
SK73494A3 (en) 1995-03-08
SE9103752D0 (sv) 1991-12-18
WO1993012085A1 (en) 1993-06-24
SI9200405A (en) 1993-06-30
US5585378A (en) 1996-12-17
ZA929700B (en) 1993-08-10
IL104107A0 (en) 1993-05-13
AP9200464A0 (en) 1993-01-31
BG98815A (bg) 1995-05-31
AP389A (en) 1995-08-02
HUT69704A (en) 1995-09-28
FI942913A (fi) 1994-08-17
CN1034939C (zh) 1997-05-21
AU675055B2 (en) 1997-01-23
NO942316L (no) 1994-06-17
AU3175993A (en) 1993-07-19
SK278321B6 (en) 1996-10-02
HU9401844D0 (en) 1994-09-28
PL170736B1 (pl) 1997-01-31
CN1079464A (zh) 1993-12-15
FI942913A0 (fi) 1994-06-17
CZ146694A3 (en) 1995-06-14
CA2124826A1 (en) 1993-06-24
EP0624156A1 (en) 1994-11-17

Similar Documents

Publication Publication Date Title
MX9207382A (es) Nuevos compuestos que tienen actividad terapeutica intermediarios para su preparacion, proceso para obtencion de tales compuestos y formulacion farmaceutica que los contiene.
MX9301929A (es) Derivados de pirimidina y procedimientos para su preparacion.
MX9204354A (es) Compuestos heterociclicos de 5 miembros, procedimiento para prepararlos y composiciones farmaceuticas que los contienen.
ECSP941104A (es) Derivados de 2,6 diaminopurina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
MX9300407A (es) Derivados azabiciclicos usados en la fabricacion de medicamentos, composiciones que los contienen y procedimiento para su preparacion.
ES2095432T3 (es) Derivados de 2,4-tiazolidin-diona, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES2054860T3 (es) Nuevos derivados de 9-halogeno-(z)-prostaglandinas, procedimiento para su preparacion, asi como a su utilizacion como medicamentos.
AR027437A1 (es) Derivados de purina
MX9204140A (es) Nuevos derivados de analogos de taxol, procedimiento para su preparacion y composicion farmaceutica que los contienen.
ES2081187T3 (es) Nuevas naftil-alquil-aminas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen.
AR004700A1 (es) 1alfa, 26 dihidroxi-d-homo-vitamina d3, una composicion farmaceutica que la comprende, un procedimiento para su preparacion y el uso de los mismos en laelaboracion de un medicamento
ES2169147T3 (es) Derivados de beta-carbolina agonistas de la melatonina, sus procedimientos de preparacion y su utilizacion a titulo de medicamento.
IT1170214B (it) Composizione farmaceutica per la cura delle arteriopatie periferiche
ES2103116T3 (es) Nuevos compuestos bi-aromaticos derivados de amida, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones.
MX9300628A (es) Nuevos derivados de taxano, procedimiento para su preparacion y composicion farmaceutica que los contiene.
MX9303572A (es) Inhibidores de proteasa del sindrome de inmunodeficiencia humana, procedimiento para su preparacion y formualcion farmaceutica que los contiene.
ES2129112T3 (es) Compuestos aromaticos policiclicos, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones.
ES8306483A1 (es) Procedimiento de preparacion de las dibezooxepinas sustituidas y de sus sales de adicion con un acido mineral u organico
AR018347A1 (es) 1h-indazoles 1,5 y 3-o-sustituidos y sus sales fisiologicamente tolerables, utilizacion de los mismos para la preparacion de medicamentos, procedimientospara preparar dichos compuestos, las composiciones y preparaciones farmaceuticas que los contienen, y la utilizacion de dichos compuestos y prepara
AR001354A1 (es) Compuestos bi-aromaticos derivados de amida, composiciones farmacéuticas y cosméticas que los contien, y utilización de dichos compuestos y composición cosmética.
ES2059130T3 (es) Composiciones farmaceuticas que contienen ipriflavona, procedimiento para su preparacion y uso terapeutico relacionado.
ES2043943T3 (es) Procedimiento para la preparacion de compuestos con actividad analgesica central.
AR004726A1 (es) Derivados 25-hidroxi-16-eno-26,27-bis homo-colecalciferol, compuestos intermediarios para su preparacion, composiciones farmaceuticas que loscontienen y uso de dichos derivados para fabricar un medicamento.
ES2172023T3 (es) Nuevos derivados tetrahidro-piridinicos sustituidos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES495826A0 (es) Procedimiento para la obtencion de acido fosfonohidroxiace- tico